Apitope Is A European Biotech Company Founded In 2002 By Professor David Wraithoriginating From The University Of Bristolbased In Diepenbeekbelgiumwith Research Activities In The Ukapitope Specializes In Developing Antigen Specific Immunotherapies For Autoimmune And Allergic Diseasesthe Company Utilizes Peptide Based Therapies To Help Restore The Body S Natural Immune Tolerance Apitope S Product Pipeline Includes Several Promising Candidatesatx Ms 1467 Is The Lead Candidate For Treating Multiple Sclerosisnoted For Its Efficacy And Safetyatx Gd 59 Aims To Be The First Disease Modifying Treatment For Gravesdiseaseaddressing A Long Standing Need For Innovation In This Areathe Company Is Also Developing Therapies For Conditions Such As Uveitisfactor Viii Inhibitorsmyocarditisand Rheumatoid Arthritisshowcasing Its Commitment To Addressing A Range Of Autoimmune Diseases
